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SI-1. SPE-GEMS/MS microchip fabrication 
SPE-GEMS/MS microchip was fabricated by scanning laser ablation. Microchannels 
were drilled in a polyimide (PI) substrate (125 µm     k  D     ™K p   ® p    m    f  m  
Dupont) by photoablation with an ArgonFluoride excimer laser (Lambda Physics LPX 210I). 
The laser was operated at 193 nm wave length with pulse width ~ 20 ns, energy of 0.35 J and 
frequency of 50 Hz. Depth and width of all microchannels were 50 and 100 µm, respectively. A 
round chamber (diameter of 500 µm, depth of 50 µm) for the trapping of the magnetic SPE 
sorbent was created using laser ablation in a static shot mode. After fabrication the quality of the 
photoablated substrate was inspected under a laser scanning microscope VK-8710 (Keyence 
Corporation). The electrode microchannel was filled with conductive carbon ink (Electrador, 
Electra Polymer & Chemicals Ltd.) and was cured for 30 min at 80 ºC in the oven. Finally, the 
microchip was covered with a 25/10 µm thick polyethylene/polyethyleneterephthalate (PE/PET) 
layer using a lamination apparatus (Morane Senator) at 130 ºC and 3 bars. For improving the 
lamination, the microchip was additionally cured for 1 h at 80 °C in the oven. To facilitate the 
electrospray formation, the tip of the microchannel A was cut in a V-shape and the microchip 
was ready to use. 
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SI-2. SEM and TEM images of C8-Fe3O4@mSiO2 microspheres 
 
Figure SI-2. Images of the C8-Fe3O4@mSiO2 microspheres obtained by a) HR-SEM, 0.5 kV; b) HR-
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SI-3. Model peptide mixture analysis 
Table SI-3. Sensitivity and preconcentration efficiency of SPE-GEMS/MS analysis of model 
peptide mixture. 
C8-Fe3O4@mSiO2 microspheres  













Angiotensin I 1296.48 5 50/65 15 150/195 0.15-10 50 
Insulin chain B oxidized 3495.89 1 10/35 3 30/105 0.03-4 200 
ACTH (1-24) 2933.44 1 10/30 3 30/90 0.03-5 240 
Commercial C8-coated magnetic beads  













Angiotensin I 1296.48 25 250/325 75 750/975 0.75-1 15 
Insulin chain B oxidized 3495.89 10 100/350 30 300/1050 0.3-0.6 20 
ACTH (1-24) 2933.44 50 500/1500 200 2000/6000 0.2-0.7 5 
MW – molecular weight; LOD – limit of detection; LOQ – limit of quantification; LDR – estimated linear dynamic 
range of analyte amount; EF – enrichment factor, calculated vs model peptide mixture analysis using plain 
microchip emitter, i.e. microchip without SPE sorbent. Sample volume loaded: 10 µl. 
LOD is defined as 3 signal-to-noise ratio, LOQ is defined as 10 signal-to-noise ratio, 
while EF is defined as peptide peak signal-to-noise ratio obtained with preconcentration × 
dilution factor/peptide peak signal-to-noise ratio obtained without preconcentration. LDR is 




SI-4. Peptides identified from BSA tryptic digest 
Table SI-4.1. Putative peptides
§
 identified from SPE-GEMS/MS analysis using 75 fmol of the 






z Probability Hyperscore 
D.C’’C’EKQEPERNEC’FLSHK.D 2232.9 559.2 4 0.9873 325 
K.GLVLIAFSQYLQQC’PFDEH.V 2264.1 567.0 4 0.9892 284 
L.RETYGDMADC’C’EKQEPER.N 2272.9 569.2 4 0.9874 319 
L.RETYGDM”ADC’C’EKQEPER.N 2288.9 573.2 4 0.9866 301 
Q.QC’PFDEHVKLVNELTEFAK.T 2303.1 576.8 4 0.9809 331 
-.nM”KWVTFISLLLLFSSAYSR.G 2319.2 580.8 4 0.9885 333 
K.VGTRC’C’TKPESERM”PC’TED.Y 2327.9 582.9 4 0.9812 324 
-.nMKWVTFISLLLLFSSAYSRG.V 2360.3 591.0 4 0.9874 322 
K.AFDEKLFTFHADIC’TLPDTE.K 2369.1 593.3 4 0.9872 330 
E.IARRHPYFYAPELLYYANK.Y 2384.2 597.1 4 0.9874 318 
K.E*C’C’HGDLLEC’ADDRADLAKY.L 2391.9 599.0 4 0.9809 275 
Q.NC’DQFEKLGEYGFQNALIVR.Y 2400.2 601.0 4 0.9847 288 
Q.EC’C’QAEDKGAC’LLPKIETMR.E 2408.1 603.0 4 0.9847 288 
K.PKATEEQLKTVMENFVAFVDK.C 2423.2 606.8 4 0.9806 335 
W.VTFISLLLLFSSAYSRGVFRR.D 2431.4 608.8 4 0.9807 333 
A.DESHAGC’EKSLHTLFGDELC’K.V 2432.1 609.0 4 0.9868 304 
K.PKATEEQLKTVM”ENFVAFVDK.C 2439.2 610.8 4 0.9803 338 
A.SLRETYGDMADC’C’EKQEPER.N 2473.0 619.3 4 0.9874 323 
A.SLRETYGDM”ADC’C’EKQEPER.N 2489.0 623.3 4 0.9851 290 
Y.E*IARRHPYFYAPELLYYANK.Y 2495.3 624.8 4 0.9812 316 
K.nWVTFISLLLLFSSAYSRGVFR.R 2503.4 626.9 4 0.987 292 
Y.LQQC’PFDEHVKLVNELTEFAK.T 2544.3 637.1 4 0.9857 294 
A.TLEEC’C’AKDDPHAC’YSTVFDK.L 2545.1 637.3 4 0.9859 295 
H.KPKATEEQLKTVMENFVAFVDK.C 2551.3 638.8 4 0.9804 337 
F.QEC’C’QAEDKGAC’LLPKIETM”R.E 2552.1 639.0 4 0.9869 305 
K.LVNELTEFAKTC’VADESHAGC’EK.S 2607.2 652.8 4 0.9905 285 
K.WVTFISLLLLFSSAYSRGVFRR.D 2617.5 655.4 4 0.985 294 
C.IAEVEKDAIPENLPPLTADFAEDK.D 2624.3 657.1 4 0.9873 313 
K.E*C’C’DKPLLEKSHC’IAEVEKDAI.P 2625.2 657.3 4 0.9871 309 
M.nKWVTFISLLLLFSSAYSRGVFR.R 2631.5 658.8 4 0.9876 296 
K.SLHTLFGDELC’KVASLRETYGDM.A 2641.3 661.3 4 0.9867 303 
F.DEKLFTFHADIC’TLPDTEKQIK.K 2648.3 663.1 4 0.9869 336 
R.E*TYGDMADC’C’EKQEPERNEC’F.L 2649.0 663.3 4 0.9835 283 
R.E*TYGDM”ADC’C’EKQEPERNEC’F.L 2665.0 667.3 4 0.9874 319 
R.M C’TEDY S I NR C’V HEKT.  2704.3 677.1 4 0.9847 357 
K.S HT FGDE C’KVAS RETYGDMA.D 2712.3 679.1 4 0.9824 279 
-.MKWVTFISLLLLFSSAYSRGVFR.R 2720.5 681.1 4 0.9879 381 
K.S HT FGDE C’KVAS RETYGDM”A.D 2728.3 683.1 4 0.9851 290 
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z Probability Hyperscore 
R.RHPYFYAPELLYYANKYNGVFQ.E 2752.3 689.1 4 0.9873 314 
E.RMPC’TEDYLSLILNRLC’VLHEK.T 2759.4 690.9 4 0.981 329 
H.C’IAEVEKDAIPENLPPLTADFAEDK.D 2784.4 697.1 4 0.9855 351 
K.ATEEQLKTVM”ENFVAFVDKC’C’AAD.D 2791.3 698.8 4 0.9811 312 
A.FLGSFLYEYSRRHPEYAVSVLLR.L 2801.5 701.4 4 0.986 296 
K.LVNELTEFAKTC’VADESHAGC’EKSL.H 2807.3 702.8 4 0.9865 300 
R.E*TYGDMADC’C’EKQEPERNEC’FLS.H 2849.1 713.3 4 0.987 333 
K.AFDEKLFTFHADIC’TLPDTEKQIK.K 2866.4 717.6 4 0.9847 368 
T.YGDM”ADC’C’EKQEPERNEC’FLSHK.D 2918.2 730.6 4 0.9874 319 
K.EYEATLEEC’C’AKDDPHAC’YSTVFDK.L 3037.2 760.3 4 0.9867 319 
R.RPC’FSALTPDETYVPKAFDEKLFTFHAD.L 3301.6 826.4 4 0.9811 314 
T.E*FAKTC’VADESHAGC’EKSLHTLFGDELC’K.V 3320.5 831.1 4 0.9809 309 
R.LAKEYEATLEEC’C’AKDDPHAC’YSTVFDK.L 3349.5 838.4 4 0.9843 290 
K.E*C’C’HGDLLEC’ADDRADLAKYIC’DNQDTI.S 3351.4 838.9 4 0.9805 378 
K.C’C’TESLVNRRPC’FSALTPDETYVPKAFDE.K 3461.6 866.4 4 0.9845 358 
A.LTPDETYVPKAFDEKLFTFHADIC’TLPDTEK.Q 3640.8 911.2 4 0.9874 321 
K.EC’C’DKPLLEKSHC’IAEVEKDAIPENLPPLTADF.A 3837.8 960.5 4 0.986 346 
L.QQC’PFDEHVKLVNELTEFAKTC’VADESHAGC’EK.S 3875.8 969.9 4 0.9813 276 
K.GLVLIAFSQYLQQC’PFDEHVKLVNELTEFAKTC’.V 3896.9 975.2 4 0.987 307 
§
Complete list of identified peptides including peptide isoforms with various modifications. 
C’ –      x  m   m        s        s    ; C’’ – (R)-5-oxoperhydro-1,4-thiazine-3-carboxylic acid, 
product of S- carboxyamidomethyl cysteine cyclization at the N-terminus; E* – pyroglutamic acid, 
product of glutamic acid cyclisation at the N-terminus; M” – methionine sulfoxide; nX – carbamylation of 
X at N-terminus. 
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Table SI-4.2. Putative peptides
§
 identified from SPE-GEMS/MS analysis using 75 fmol of the 






z Probability Hyperscore 
K.C’’C’TES VNR.R 1120.5 561.2 2 0.9998 504 
R.C’’C’TK ESER.M 1148.5 575.2 2 0.9998 451 
K.LVNELTEFAK.T 1162.6 582.3 2 0.9996 574 
K.EC’C’DK   EK.S 1290.6 646.3 2 0.9994 345 
K.HLVDEPQNLIK.Q 1304.7 653.4 2 0.9999 559 
K.TVMENFVAFVDK.C 1398.7 700.3 2 0.9933 477 
K.TVM”ENFVAFVDK.C 1414.7 708.3 2 0.9983 256 
K.S HT FGDE C’K.V 1418.7 710.4 2 0.9999 634 
K.YIC’DNQDTISSK.  1442.7 722.3 2 0.9999 747 
K.EYEAT EEC’C’AK.D 1501.7 751.8 2 0.9996 616 
K.VPQVSTPTLVEVSR.S 1510.8 756.4 2 0.9998 567 
R.KVPQVSTPTLVEVSR.S 1638.9 820.5 2 0.9999 483 
K.G V IAFSQY QQC’ FDEH.V 2264.1 567.0 4 0.9883 271 
K.VGTRC’C’TK ESERM” C’TED.Y 2327.9 583.0 4 0.9796 308 
-.nMKWVTFISLLLLFSSAYSRG.V 2360.3 591.1 4 0.9796 308 
E.IARRHPYFYAPELLYYANK.Y 2384.2 597.1 4 0.9796 307 
A.DESHAGC’EKS HT FGDE C’K.V 2432.1 609.0 4 0.9796 306 
R.FKDLGEEHFKGLVLIAFSQYL.Q 2453.3 614.3 4 0.9796 305 
K.G V IAFSQY QQC’ FDEHVK.  2491.3 623.8 4 0.9867 625 
V.HKEC’C’HGD  EC’ADDRAD AK.Y 2512.1 629.0 4 0.9796 311 
Y. QQC’ FDEHVK VNE TEFAK.T 2544.3 637.1 4 0.9796 302 
K.HKPKATEEQLKTVMENFVAFVDK.C 2688.4 673.1 4 0.981 324 
-.MKWVTFISLLLLFSSAYSRGVFR.R 2720.5 681.1 4 0.9816 300 
-.M”KWVTFISLLLLFSSAYSRGVFR.R 2736.5 685.1 4 0.9817 302 
R.RHPYFYAPELLYYANKYNGVFQ.E 2752.3 689.1 4 0.9796 304 
E.ATLEEC’C’AKDDPHAC’YSTVFDKLK.H 2857.3 715.3 4 0.9796 311 
§
Complete list of identified peptides including peptide isoforms with various modifications. 
C’ –      x  m   m        s        s    ; C’’ – (R)-5-oxoperhydro-1,4-thiazine-3-carboxylic acid, 
product of S- carboxyamidomethyl cysteine cyclization at the N-terminus; E* – pyroglutamic acid, 
product of glutamic acid cyclisation at the N-terminus; M” – methionine sulfoxide; nX – carbamylation of 
X at N-terminus. 
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SI-5. Peptides identified from Trastuzumab digested with Sap9 
Table SI-5. Putative peptides
§
 identified from SPE-GEMS/MS analysis using 33 fmol of the 









R.WGGDGFYAMDYWGQGTLVTVSS.A 2396.0 600.0 4 0.9753 315 
K.C’KVSNKALPAPIEKTISKAKGQP.R 2464.4 617.1 4 0.977 335 
K.VSNKALPAPIEKTISKAKGQPREP.Q 2558.5 640.6 4 0.9676 313 
R.WGGDGFYAM”DYWGQGTLVTVSSAS.T 2570.1 643.5 4 0.9665 285 
K.E*YKC’KVSNKALPAPIEKTISKAK.G 2584.4 647.1 4 0.9834 310 
L.E*KTISKAKGQPREPQVYTLPPSR.E 2591.4 648.9 4 0.9636 303 
S.Q*ESVTEQDSKDSTYSLSSTLTLSK.A 2616.2 655.1 4 0.9615 353 
W.QQGNVFSC’SVM”HEALHNHYTQK.S 2630.2 658.6 4 0.9781 345 
G.GSLRLSC’AASGFNIKDTYIHWVR.Q 2650.3 663.6 4 0.9612 363 
K.VDKKVEPKSC’DKTHTC’PPC’PAPE.L 2679.2 670.8 4 0.9686 312 
K.VSNKALPAPIEKTISKAKGQPREPQ.V 2686.5 672.6 4 0.9703 323 
L.NGKEYKC’KVSNKALPAPIEKTISK.A 2702.5 676.6 4 0.9645 305 
L.C’NVNHKPSNTKVDKKVEPKSC’DK.T 2711.3 678.8 4 0.9602 297 
P.E*DFATYYC’QQHYTTPPTFGQGTK.V 2721.2 681.3 4 0.979 362 
F.NIKDTYIHWVRQAPGKGLEWVAR.L 2736.5 685.1 4 0.9724 328 
S.KNTAYLQM”NSLRAEDTAVYYC’SR.W 2769.3 693.3 4 0.965 331 
K.DYFPEPVTVSWNSGALTSGVHTFPAV.L 2777.3 695.3 4 0.9817 341 
R.WGGDGFYAMDYWGQGTLVTVSSASTK.G 2783.3 696.8 4 0.9843 313 
G.TKVEIKRTVAAPSVFIFPPSDEQLK.S 2799.5 700.9 4 0.9666 346 
R.WQQGNVFSC’SVM”HEALHNHYTQK.S 2816.3 705.1 4 0.9875 359 
K.ALPAPIEKTISKAKGQPREPQVYTLP.P 2831.6 708.9 4 0.9738 341 
K.VQWKVDNALQSGNSQESVTEQDSKDS.T 2878.3 720.6 4 0.9609 341 
K.VDNALQSGNSQESVTEQDSKDSTYSLS.S 2888.3 723.1 4 0.963 322 
E.YKC’KVSNKALPAPIEKTISKAKGQPR.E 2911.6 728.9 4 0.9733 335 
K.ALPAPIEKTISKAKGQPREPQVYTLPP.S 2928.6 733.2 4 0.9684 300 
R.VVSVLTVLHQDWLNGKEYKC’KVSNK.A 2943.6 736.9 4 0.9834 336 
L.HQDWLNGKEYKC’KVSNKALPAPIEK.T 2952.5 739.1 4 0.9766 331 
K.C’KVSNKALPAPIEKTISKAKGQPREPQ.V 2974.6 744.7 4 0.9682 311 
K.HKVYAC’EVTHQGLSSPVTKSFNRGEC’.- 2990.4 748.6 4 0.9829 388 
K.VEIKRTVAAPSVFIFPPSDEQLKSGTASV.V 3072.7 769.2 4 0.9664 342 
A.M”DYWGQGTLVTVSSASTKGPSVFPLAPSSK.S 3113.5 779.4 4 0.9655 374 
R.E*PQVYTLPPSREEMTKNQVSLTC’LVKGF.Y 3232.6 809.2 4 0.9727 368 
T.YRVVSVLTVLHQDWLNGKEYKC’KVSNK.A 3262.7 816.7 4 0.9729 377 
L.TVLHQDWLNGKEYKC’KVSNKALPAPIEK.T 3265.8 817.4 4 0.9612 288 
R.SGTDFTLTISSLQPEDFATYYC’QQHYTT.P 3273.4 819.4 4 0.9703 300 
N.KALPAPIEKTISKAKGQPREPQVYTLPPSR.E 3299.9 826.0 4 0.9718 332 
P.IEKTISKAKGQPREPQVYTLPPSREEMTK.N 3340.8 836.2 4 0.962 300 
R.YADSVKGRFTISADTSKNTAY QM”NS RAE.D 3352.6 839.2 4 0.9734 314 
K.VSNKALPAPIEKTISKAKGQPREPQVYTLPP.S 3356.9 840.2 4 0.9741 347 
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Q.ESVTEQDSKDSTYSLSSTLTLSKADYEKHK.V 3376.6 845.2 4 0.9728 378 
R.WQQGNVFSC’SVM”HEA HNHYTQKS S S .G 3400.6 851.2 4 0.9618 318 
S.NKALPAPIEKTISKAKGQPREPQVYTLPPSR.E 3413.9 854.5 4 0.9688 317 
K.ALPAPIEKTISKAKGQPREPQVYTLPPSREE.M 3429.8 858.5 4 0.9611 296 
R.T EVTC’VVVDVSHED EVKFNWYVDGVEVH.N 3483.6 871.9 4 0.9646 329 
K.GQ RE QVYT   SREEMTKNQVS TC’ VK.G 3484.8 872.2 4 0.9738 292 
V.SNKALPAPIEKTISKAKGQPREPQVYTLPPSR.E 3500.9 876.2 4 0.9724 328 
R.AEDTAVYYC’SRWGGDGFYAM”DYWGQGT VTV.S 3553.5 889.4 4 0.9659 371 
R.FTISADTSKNTAY QMNS RAEDTAVYYC’SR.W 3575.7 894.9 4 0.9706 312 
K.C’KVSNKA  A IEKTISKAKGQ RE QVYT   .S 3645.0 912.3 4 0.9732 351 
N.AKTKPREEQYNSTYRVVSVLTVLHQDWLNGK.E 3658.9 915.7 4 0.9708 385 
F.T TISS Q EDFATYYC’QQHYTT  TFGQGTK.V 3679.7 920.9 4 0.973 307 
K.C’’KVSNKA  A IEKTISKAKGQ RE QVYT   S.R 3715.0 929.8 4 0.9717 387 
K.E*YKC’KVSNKA  A IEKTISKAKGQ RE QVYT .  3853.1 964.3 4 0.9695 315 
R.AEDTAVYYC’SRWGGDGFYAM”DYWGQGT VTVSSAS.T 3885.7 972.4 4 0.9648 330 
R.E QVYT   SREEM”TKNQVS TC’ VKGFY SDIA.V 3912.9 979.2 4 0.9746 394 
R.SGTDFT TISS Q EDFATYYC’QQHYTT  TFGQG.T 3957.8 990.4 4 0.9804 385 
R.EEM”TKNQVS TC’ VKGFY SDIAVEWESNGQ ENNY.K 4191.9 1048.9 4 0.9661 369 
R.AEDTAVYYC’SRWGGDGFYAM”DYWGQGT VTVSSASTKG .S 4268.9 1068.2 4 0.9607 369 
R.FSGSRSGTDFT TISS Q EDFATYYC’QQHYTT  TFG.Q 4306.9 1077.7 4 0.9642 327 
R.E* QVYT   SREEM”TKNQVS TC’ VKGFY SDIAVEW.E 4309.1 1078.3 4 0.9737 368 
K.SGTASVVC’  NNFY REAKVQWKVDNA QSGNSQESVTE.Q 4325.1 1082.3 4 0.9776 363 
Y.VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK.E 4508.3 1128.1 4 0.9672 404 
T.YYC’QQHYTT  TFGQGTKVEIKRTVAA SVFIF  SDEQ K.S 4728.4 1183.1 4 0.9654 375 
G.GS R SC’AASGFNIKDTYIHWVRQA GKG EWVARIY TNGYTR.Y 5008.6 1253.1 4 0.9763 381 
-.E*VQ VESGGG VQ GGS R SC’AASGFNIKDTYIHWVRQA GKG EW 
VA.R 
5218.7 1305.7 4 0.9721 375 
V. HQDW NGKEYKC’KVSNKA  A IEKTISKAKGQ RE QVYT   SR.E 5399.9 1351.0 4 0.9689 301 
K.NTAY QMNS RAEDTAVYYC’SRWGGDGFYAMDYWGQGT VTVSSAST
KG.P 
5447.5 1362.9 4 0.9607 369 
K.A K  IYSASF YSGV SRFSGSRSGTDFT TISS Q EDFATYYC’QQHYT
TPPTFGQG.T 
6542.1 1636.5 4 0.9725 329 
§
Complete list of identified peptides including peptide isoforms with various modifications. 
C’ –      x  m   m        s        s    ; C’’ – (R)-5-oxoperhydro-1,4-thiazine-3-carboxylic acid, 
product of S- carboxyamidomethyl cysteine cyclization at the N-terminus; E* – pyroglutamic acid, 
product of glutamic acid cyclisation at the N-terminus; Q* – pyroglutamic acid, product of glutamine 
cyclisation at the N-terminus; M” – methionine sulfoxide. 
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SI-6. Effect of various sample loading schemes on the SPE-GEMS/MS analysis 
of antibodies mixture digested with Sap9 
Table SI-6. SPE-GEMS/MS analysis of IgG mixture digested with Sap9: various sample loading 
schemes 
Name 















Lc 60 72 81 
Hc 37 54 69 
Bevacizumab, 
IgG1 
Lc 43 76 84 
Hc 36 61 77 
Trastuzumab, 
IgG1 
Lc 48 80 85 
Hc 51 66 79 
Natalizumab, 
IgG4 
Lc 41 69 81 
Hc 54 73 83 
Panitumumab, 
IgG2 
Lc 36 56 67 
Hc 45 51 62 
Rituximab, 
IgG1 
Lc 36 57 74 
Hc 54 60 75 
Total sample loading 
time 
10 min 15 min 20 min 




SI-7. Representative CID mass spectra obtained during SPE-GEMS/MS 
analysis of IgG mixture digested with Sap9 
 
Figure SI-7. Representative CID mass spectra of CDR-containing peptides with assignments of their 
respective b, y product ions, identified by SPE-GEMS/MS analysis of IgG mixture digested with Sap9. 
Selected peptides derived from the Hc of a) Rituximab, IgG1, with CDR 3, MW=3858.8 Da; b) 
Bevacizumab, IgG1, with CDR 1, MW=4541.3 Da; c) Natalizumab, IgG4, with CDR 3, MW=3382.5 Da; 
d) Panitumumab, IgG2, with CDR 1, MW=3008.4 Da. Insets: corresponding peptide sequences with 
assigned peptide backbone cleavage sites and underlined CDRs. Experimental conditions: C8-
Fe3O4@mSiO2 microspheres as a SPE sorbent, 333 fmol (50 ng) of loaded sample, equimolar mixture. 
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